Close
  Indian J Med Microbiol
 

Figure 4: p-200 placebo to 200 mg dose; p-100 placebo to 100 mg dose. reSURFACE-1 trial PASI and PGA 0/1 response at week 28 for tildrakizumab 100 mg, 200 mg, and patients shifted from placebo to tildrakizumab 200 mg dose (p-200) and 100 mg dose (p-100)

Figure 4: p-200 placebo to 200 mg dose; p-100 placebo to 100 mg dose. reSURFACE-1 trial PASI and PGA 0/1 response at week 28 for tildrakizumab 100 mg, 200 mg, and patients shifted from placebo to tildrakizumab 200 mg dose (p-200) and 100 mg dose (p-100)